Proton Pump

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1354 Lansoprazole <1 mg/mL 74 mg/mL 14 mg/mL
S1389 Omeprazole <1 mg/mL 69 mg/mL 13 mg/mL
S1413 Bafilomycin A1(Baf-A1) <1 mg/mL 6 mg/mL <1 mg/mL
S1743 NEXIUM (esomeprazole magnesium) <1 mg/mL 143 mg/mL 143 mg/mL
S4075 Zinc Pyrithione <1 mg/mL 30 mg/mL <1 mg/mL
S4845 Rabeprazole 71 mg/mL 71 mg/mL 71 mg/mL
S5058 Revaprazan Hydrochloride -1 mg/mL 16 mg/mL -1 mg/mL
S3666 Ilaprazole <1 mg/mL 73 mg/mL 14 mg/mL
S2222 PF-3716556 <1 mg/mL 79 mg/mL 79 mg/mL
S4099 Dexlansoprazole <1 mg/mL 74 mg/mL <1 mg/mL
S4212 Tenatoprazole <1 mg/mL 46 mg/mL 14 mg/mL
S4665 Rebeprazole sodium 76 mg/mL 76 mg/mL 76 mg/mL
S4538 Pantoprazole sodium 81 mg/mL 81 mg/mL 81 mg/mL
S2105 Pantoprazole <1 mg/mL 76 mg/mL 76 mg/mL
Catalog No. Information Product Use Citations Product Validations
S1354

Lansoprazole

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.
S1389

Omeprazole

Omeprazole is a proton pump inhibitor, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
S1413

Bafilomycin A1(Baf-A1)

Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM.
Immunity, 2016, 45(4):944
Front Immunol, 2017, 8:553
Cardiovasc Diabetol, 2016, 15(1):136
S1743

NEXIUM (esomeprazole magnesium)

Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion.
S4075

Zinc Pyrithione

Zinc pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
S4845New

Rabeprazole

Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach.
S5058New

Revaprazan Hydrochloride

Revaprazan Hydrochloride is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects.
S3666New

Ilaprazole

Ilaprazole is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
S2222

PF-3716556

PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.
S4099

Dexlansoprazole

Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties.
S4212

Tenatoprazole

Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM.
S4665

Rebeprazole sodium

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.
S4538

Pantoprazole sodium

Pantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
S2105

Pantoprazole

Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Tags: proton pump inhibition | PPI therapy | PPI medication | PPIs drugs | proton pump inhibitors medications | proton pump inhibitor drugs | PPI treatment | proton pump inhibitors list | proton pump inhibitor therapy | proton pump inhibitor treatment | proton pump inhibitors cancer | PPI prescription | proton pump inhibitor guidelines | proton pump inhibitor function | proton pump inhibitors contraindications | PPI contraindications proton pump inhibitor review